Year 2008 / Volume 100 / Number 11
Original
Adalimumab induction and maintenance therapy for Crohn

pp. 676-681

López Palacios, N. / Mendoza, J. L. / Taxonera, C. / Lana, R. / Fuentes Ferrer, M. / Díaz-Rubio, M.

Abstract
Background: adalimumab has been shown in placebo-controlled clinical trials and uncontrolled studies to be effective in luminal and perianal fistulizing CD.

Objective: to evaluate the efficacy and safety of adalimumab for induction and maintenance therapy in CD.

Methods: twenty-two patients with CD treated with adalimumab (16 for luminal disease and 6 for active perianal fistulizing disease) were included. Twenty-one patients had previously received IFX. All patients received induction therapy with 160 mg s.c. at week 0, and 80 mg s.c. at week 2. Responders received maintenance therapy with 40 mg s.c. every 14 days. Response was assessed at 4 weeks after the initial dose, and classified as remission, partial response, or non-response.

Results: after induction, 25% of patients with luminal disease had a complete remission, and 56.3% had a partial response. Clinical response was maintained in 71.6% of patients at 1 year, in 53.7% at 18 months, and in 35.8% at 48 months. No differences in response were observed between patients with hypersensitivity reactions or loss of response to IFX.

All patients with perianal fistulizing disease (n = 6) had been previously treated with IFX. After induction 16.7% entered remission, and 66.7% had a partial response. All patients maintained remission or response over time, with a median follow-up of 15 months.

Conclusions: adalimumab is an effective and safe treatment for the induction and maintenance of response in luminal and perianal fistulizing CD. These results confirm that the findings obtained in controlled clinical trials are reproducible in clinical practice.
New comment
Comments
No comments for this article
Related articles
Citation tools
López Palacios, N. / Mendoza, J. L. / Taxonera, C. / Lana, R. / Fuentes Ferrer, M. / Díaz-Rubio, M.. Adalimumab induction and maintenance therapy for Crohn. 676-681


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 49 visits.
This article has been downloaded 11 times.
Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology